https://mindmedicinelaw.com/briefing/ketamine-s-long-term-anxiolytic-effects-in-female-rats-20260701-18353The Psychedelic Journalen2026-07-02T22:05:09.503105+00:00Ketamine's Long-Term Anxiolytic Effects in Female Ratsketamine research, anxiolytic effects, female rats, oxidative stress, psychiatric treatment, treatment-resistant depression, sex-specific studies, neuroscience, preclinical research, Wistar-Kyoto ratshttps://mindmedicinelaw.com/briefing/psychedelics-role-in-social-cognition-new-insights-20260701-18040The Psychedelic Journalen2026-07-01T22:03:11.723956+00:00Psychedelics' Role in Social Cognition: New Insightspsychedelics, social cognition, psychiatric disorders, serotonergic drugs, MDMA, ketamine, clinical trials, therapeutic interventions, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/oregon-psilocybin-program-expansion-sparks-safety-concerns-20260701-18070The Psychedelic Journalen2026-07-01T15:06:03.758509+00:00Oregon Psilocybin Program Expansion Sparks Safety ConcernsOregon psilocybin program, psilocybin safety concerns, psychedelic therapy regulation, Measure 109, psilocybin research, public health policy, therapeutic psilocybin use, psychedelic facilitator traininghttps://mindmedicinelaw.com/briefing/va-initiates-mdma-trial-for-ptsd-in-veterans-20260701-18067The Psychedelic Journalen2026-07-01T15:05:40.960583+00:00VA Initiates MDMA Trial for PTSD in VeteransVA MDMA trial, PTSD treatment, veteran mental health, psychedelic therapy, MDMA-assisted therapy, clinical trial, psychedelic research, veterans affairs, mental health care, post-traumatic stress disorderhttps://mindmedicinelaw.com/briefing/dea-proposes-schedule-i-status-for-4-new-substances-20260701-17986The Psychedelic Journalen2026-07-01T15:05:29.485066+00:00DEA Proposes Schedule I Status for 4 New SubstancesDEA, Schedule I, psychedelic research, controlled substances, drug policy, temporary scheduling, therapeutic potential, regulatory controls, synthetic compounds, psychoactive substanceshttps://mindmedicinelaw.com/briefing/congressional-bill-aims-to-codify-psychedelics-policy-20260701-18068The Psychedelic Journalen2026-07-01T15:05:12.135436+00:00Congressional Bill Aims to Codify Psychedelics Policypsychedelics policy, bipartisan bill, Trump executive order, federal regulation, psychedelic research, industry impact, regulatory framework, mental health, therapeutic benefits, legislative efforthttps://mindmedicinelaw.com/briefing/fda-approval-of-psilocybin-therapy-possible-by-2027-20260701-18069The Psychedelic Journalen2026-07-01T15:04:58.745997+00:00FDA Approval of Psilocybin Therapy Possible by 2027psilocybin therapy, FDA approval, psychedelic medicine, mental health treatment, clinical trials, drug policyhttps://mindmedicinelaw.com/briefing/ketamine-s-expanding-therapeutic-role-in-psychiatry-and-pain-20260630-18355The Psychedelic Journalen2026-07-02T22:05:33.847152+00:00Ketamine's Expanding Therapeutic Role in Psychiatry and Painketamine, glutamatergic neurotransmission, treatment-resistant depression, chronic pain management, NMDA receptor, synaptic plasticity, neuroinflammation, clinical trials, safety concerns, misuse potentialhttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-brain-circuits-long-term-insights-20260630-18334The Psychedelic Journalen2026-07-02T22:05:25.445940+00:00Psilocybin's Impact on Brain Circuits: Long-Term Insightspsilocybin, brain circuits, fronto-striatal-thalamic, serotonergic pathways, dopaminergic pathways, psychiatric conditions, neuropsychiatric disorders, clinical trials, psychedelic research, brain flexibilityhttps://mindmedicinelaw.com/briefing/implications-of-5-ht2a-and-mglur2-receptor-interaction-findings-20260630-18338The Psychedelic Journalen2026-07-02T22:05:17.658518+00:00Implications of 5-HT2A and mGluR2 Receptor Interaction Findings5-HT2A receptor, mGluR2 receptor, psychedelic research, receptor interaction, neuroscience, clinical trials, LSD, psychedelic mechanisms, therapeutic strategies, receptor colocalizationhttps://mindmedicinelaw.com/briefing/psilocybin-trial-for-anorexia-nervosa-in-adolescents-a-new-frontier-20260630-18337The Psychedelic Journalen2026-07-02T22:05:01.825554+00:00Psilocybin Trial for Anorexia Nervosa in Adolescents: A New Frontierpsilocybin, anorexia nervosa, adolescents, clinical trial, psychiatric treatment, neurobiology, functional MRI, treatment as usual, psychedelic therapy, relapse rateshttps://mindmedicinelaw.com/briefing/esketamine-nasal-spray-efficacy-and-safety-in-trd-20260630-18359The Psychedelic Journalen2026-07-02T22:04:52.764805+00:00Esketamine Nasal Spray: Efficacy and Safety in TRDesketamine nasal spray, treatment-resistant depression, rapid-acting antidepressant, NMDA receptor, clinical trial data, real-world evidence, safety profile, long-term effects, phase 3 trialshttps://mindmedicinelaw.com/briefing/psilocybin-trials-for-anorexia-in-youth-a-new-frontier-20260630-18062The Psychedelic Journalen2026-07-01T15:05:53.273153+00:00Psilocybin Trials for Anorexia in Youth: A New Frontierpsilocybin, anorexia nervosa, adolescents, clinical trials, psychedelic therapies, mental health, neuroplasticity, FDA, eating disorders, youth interventionshttps://mindmedicinelaw.com/briefing/patient-education-in-ketamine-therapies-for-mood-disorders-20260629-18048The Psychedelic Journalen2026-07-01T22:03:19.463321+00:00Patient Education in Ketamine Therapies for Mood Disordersketamine therapy, esketamine treatment, mood disorders, patient education, clinical outcomes, treatment adherence, psychedelic research, mental health, neuroscience, public health